This is a voluntary observational study, or “registry”, created to collect information about the affects of BUPHENYL® (sodium phenylbutyrate) or RAVICTITM (glycerol phenylbutyrate) Oral Liquid on women and their babies who took one of these medicines just before or during pregnancy.
Horizon Pharma, the maker of RAVICTI, designed this registry because pregnant women were excluded from clinical trials during the development of RAVICTI. So, there is limited information available about pregnant women taking RAVICTI or about their babies.
To learn more about the UCD Pregnancy Registry and to find out if you qualify for enrollment, contact a UCD Pregnancy Registry Team member toll-free at
You may also ask your healthcare provider to enroll you.
Download a free patient pamphlet about the UCD Pregnancy Registry
ANY healthcare provider caring for a patient on BUPHENYL or RAVICTI during pregnancy can enroll a patient in the UCD Pregnancy Registry.
To enroll a potential patient call
Download the UCD Pregnancy Registry Protocol (HPN-100-018)
United Biosource Corporation, Copyright 2013